In the USA or UK, the health care systems consistently deny access of B12 shots to PA patients
These comparative studies establish the pharmacological basis for the different biological profiles of MT-1 versus MT-II , with MT-1s MC1R preference explaining its predominantly pigmentary and skin photoprotection biology in contrast to MT-IIs broader melanocortin receptor activation producing pro-sexual, pro-erectile, and central appetite effects alongside pigmentation
10.1093/glycob/12.4.43R Glycobiology 166 SriramK.BenkovicS
It works for both men and women
Below is a quick snapshot of the leading therapies and their approved uses, costs, and availability OZEMPIC (Semaglutide GLP-1 agonist) Manufacturer: Novo Nordisk Dose: 2 mg weekly injectable Approved for: Type 2 diabetes (US, 2017) Cost: ~$936/month (77,600) India: Not yet available WEGOVY (Semaglutide) Novo Nordisk 2.4 mg weekly injectable Approved for chronic weight loss & heart health improvement (US, 202124) ~$1,300/month (1.08 lakh) Not available RYBELSUS (Semaglutide oral) Novo Nordisk 3 mg, 7 mg & 14 mg tablets daily Approved for Type 2 diabetes (US, 2019
